Two completely different products share the letters GHK-Cu: a perfectly sensible face serum, and an injectable with zero human trials. The person who wrote most of the glowing research also sells the serum. Women lose about a third of their skin collagen in the five years after menopause and nobody has ever tested this molecule in that group. We find that genuinely funny, in the bleak way.
The short version
Copper peptide (GHK-Cu) is sold two ways. The topical version is a reasonable low-risk cosmetic whose evidence base has a sourcing problem. The injectable version has no published human trials for any indication and adds a risk the cream does not: it puts copper into your bloodstream with no agreed dose and no monitoring standard. The route that is marketed as "stronger" is the route with less evidence and more risk. Oral collagen peptides are a separate compound with genuinely better trials, and a 2025 meta-analysis that should temper how excited you get about them.
If you are somewhere between 42 and 55 and your face changed faster in the last two years than in the ten before it, you are not imagining it and you are not doing anything wrong. Skin collagen falls steeply around menopause, and it falls fastest at the start. That is one of the best-documented physical changes of this life stage.
It is also, unfortunately, one of the most heavily marketed. Copper peptide serums, injectable GHK-Cu vials, collagen powders and "peptide facials" are all pitched at exactly this window. So this page does one thing: it separates what has been measured in humans from what has been measured in a petri dish, a rat, or a company's own unpublished file, and it tells you which of those you are being sold.
What actually happens to skin and hair in perimenopause
The core finding is old, replicated, and not controversial. Skin collagen content and dermal thickness are oestrogen-sensitive, and both drop after the menopausal transition. The most-cited synthesis of this work is Brincat and colleagues' review in Climacteric, which describes a steep early decline — on the order of 30% of skin collagen lost in the first five years after menopause, with a slower ongoing loss after that. A separate biopsy study in 32 women found collagen type I and type III both significantly lower in postmenopausal than premenopausal women, and inversely correlated with years since menopause.
That is the change. Loss of dermal collagen shows up as thinner skin, more visible fine lines, slower wound healing, and a crepey texture on the arms and chest that moisturiser does not touch.
of skin collagen lost in the first five years after menopause — and not one trial has ever tested GHK-Cu in this population, despite perimenopausal women being its main marketing target.
Hair is messier. Female pattern hair loss accelerates in midlife too, but it is driven by follicular sensitivity to androgens against a falling oestrogen background, plus thyroid disease, iron deficiency and stress — all of which are common in this demographic and all of which are treatable. It is not the same problem as dermal collagen loss, and it does not respond to the same things.
The one intervention with direct evidence in this population
Worth saying plainly, because no peptide page says it: the thing with the most human data for menopausal skin is menopausal hormone therapy. A 2023 systematic review and meta-analysis pooled 15 studies and 1,589 women aged 45–55 and found MHT increased skin thickness (SMD 1.27), collagen content (SMD 2.01) and elasticity (SMD 0.28) versus comparison. Skin dryness did not significantly differ. The authors are explicit that better trials are still needed.
Nobody prescribes hormone therapy for wrinkles, and it is not being suggested here. But if you are already weighing MHT for hot flushes or sleep, the skin data is real and it is more direct than anything in the peptide category. Our peptides and HRT guide covers the interactions that matter if you end up doing both.
The options, side by side
| Form | Route | Human evidence | Studied in women over 40? | Risk profile | Rough cost |
|---|---|---|---|---|---|
| GHK-Cu serum | Topical | Mixed Long cosmetic safety record; efficacy studies largely company-linked | Not specifically. No menopause-stratified trial exists | Low. Irritation, occasional contact sensitivity | ~$20–70 a bottle, 1–3 months' use |
| GHK-Cu injectable | Subcutaneous | No human data Zero published human trials, any indication | No | Unquantified. Systemic copper, no dosing standard, no monitoring | ~$30–70 per vial from research suppliers |
| Oral collagen peptides (skin) | Oral | Mixed Multiple RCTs; effect disappears in unfunded and high-quality studies | Yes — trials ran in women aged 35–65 | Low. GI upset in some | ~$20–45 a month at 5 g/day |
| Oral collagen peptides (bone) | Oral | Thin Two small RCTs in postmenopausal women, both positive, both small | Yes — explicitly postmenopausal | Low | Same product, same cost |
| Topical minoxidil 5% | Topical | Supported Ranked top-tier in a network meta-analysis of 13 female trials | Yes, extensively | Known and labelled: shedding, irritation, unwanted facial hair | ~$10–30 a month generic |
| "Peptide facial" / clinic infusions | Varies | No human data for the peptide component as sold | No | Depends entirely on what is in the syringe | $150–600 per session |
Costs are approximate retail ranges observed in September 2026 and move constantly. Treat them as orders of magnitude, not quotes.
Topical vs injectable GHK-Cu: settling it
This is the single most confused question in the category, and the answer runs the opposite way to how it is sold.
The sales logic goes: topical products have a delivery problem, injection bypasses it, therefore injection works better. The first half of that is a fair pharmacological point. The second half does not follow, because there is nothing on the other side of the injection to deliver to — no trial, no endpoint, no dose.
published human trials of injected GHK-Cu, for any indication, anywhere. A PubMed search for GHK-Cu returns roughly 220 papers and none indexed as a clinical trial.
| Topical GHK-Cu | Injectable GHK-Cu | |
|---|---|---|
| Human trials | Cosmetic studies exist, mostly company-run and not independently published | None. Zero, for any indication |
| Where the copper goes | Mostly stays in skin. An in vitro penetration study measured copper retained as a depot in the dermis with limited onward passage | Systemic circulation, in a bolus, at a dose nobody has established |
| Dose guidance | Concentration on the label; you can stop by washing it off | None published. Vendor protocols are invented |
| Monitoring | Not needed | No standard exists. Nobody tells you to check serum copper or ceruloplasmin |
| Reversibility | Immediate | Not immediate |
| Regulatory status | Sold lawfully as a cosmetic | Sold as "research material". Not lawfully compoundable |
| Net | Mixed Low risk, uncertain benefit | No human data Unknown risk, unknown benefit |
The sentence to keep
Injectable GHK-Cu delivers copper systemically with no established dose, no monitoring standard and a real theoretical accumulation risk. Copper toxicity is a genuine clinical entity — the NIH sets an upper intake level of 10 mg a day for adults, and chronic excess is associated with liver damage and GI symptoms. So the "more bioavailable therefore better" pitch inverts the actual risk–benefit: the route with less evidence carries more risk.
None of this means injected GHK-Cu is dangerous at the doses people use. It means nobody knows, because nobody has looked, and the people selling it have not looked either. If you are being offered it by a clinic, the honest question to ask is: "which published human trial are you dosing me from?" There is not one.
The 2026 American Journal of Sports Medicine primer on injectable peptides reviewed GHK-Cu alongside BPC-157 and TB-500 and concluded it "showed promise in wound healing and anti-inflammatory effects, but no clinical data support its use" for musculoskeletal conditions. That is orthopaedics, not dermatology, but it is the most recent independent read on the injectable route and it says the same thing.
The sourcing problem behind topical GHK-Cu
Topical copper peptide is fine. We are not about to tell you to throw out your serum. But you should know where the evidence you have read about it comes from, because it is unusually concentrated.
The major review articles that established GHK-Cu's reputation — the ones cited by essentially every skincare brand and peptide vendor — are authored by Loren Pickart, who founded and owns Skin Biology, a copper-peptide skincare company. That includes the 2008 Journal of Biomaterials Science review, the 2015 BioMed Research International review and the 2018 International Journal of Molecular Sciences review. Several of these declare no conflict of interest.
The underlying "controlled studies" those reviews describe are largely company-run and were not independently published in peer-reviewed journals. Independent controlled trials of GHK-Cu for skin ageing are very thin on the ground.
Where "regulates 4,000 genes" comes from
You will see this claim, usually alongside "resets DNA to a healthier state", on nearly every copper peptide product page. It traces to the same source — a 2014 paper titled "GHK and DNA: resetting the human genome to health". The underlying observation is a gene-expression array showing GHK shifts the expression of a large number of genes in cultured cells. That is a real measurement. "Resetting the genome to health" is a narration of that measurement, not a finding. Gene arrays routinely show thousands of expression changes from many stimuli, including ones nobody would call rejuvenating.
To be fair about it: none of this is evidence of fraud, and the mechanism is biologically plausible. GHK-Cu is a real endogenous tripeptide, it does bind copper, and copper is genuinely required for lysyl oxidase to cross-link collagen. What it is, is an evidence base with one dominant, commercially interested author and very little independent replication. Weigh it accordingly — and weigh it lightly, given that a serum costs $30 and carries almost no risk.
The gap that should annoy you
Of roughly 220 indexed GHK-Cu papers, four carry both human and female MeSH tags. A search for GHK-Cu combined with menopause, perimenopause or postmenopausal returns zero results. The single best-documented skin change of this life stage — a 30% collagen drop in five years — and the compound most aggressively marketed to the women having it have never been studied together. Not once, in forty years.
Oral collagen peptides: a different compound, better trials, a real caveat
Oral collagen peptides are not GHK-Cu and should not be lumped in with it. They are hydrolysed collagen — short chains of amino acids from animal collagen, taken as a powder, typically 2.5–5 g a day. They have been tested properly in humans, repeatedly, in women in exactly the right age band. This is one of the better-evidenced things in the whole category, and it also has the most interesting problem.
Skin
The two most-cited trials both come from Proksch and colleagues in Skin Pharmacology and Physiology in 2014. The first randomised 69 women aged 35–55 to 2.5 g, 5 g or placebo for eight weeks and found significant improvement in skin elasticity in both dose groups. The second randomised 114 women aged 45–65 to 2.5 g of a specific peptide (VERISOL) or placebo for eight weeks and reported a roughly 20% reduction in eye wrinkle volume, with biopsy findings of higher procollagen type I (65%) and elastin (18%) content in the treated group.
Those are real randomised trials, in the right women, with objective measurements. They are also small, eight weeks long, and connected to the ingredient manufacturer — one co-author heads a collagen research institute and VERISOL is a commercial branded ingredient.
The 2025 meta-analysis that changes the picture
A systematic review in the American Journal of Medicine pooled 23 RCTs and 1,474 participants. Across all 23 trials, collagen supplements significantly improved hydration, elasticity and wrinkles. But when the authors split by funding source, studies not funded by supplement or pharmaceutical companies showed no effect on any of the three, while funded studies did. Splitting by study quality gave the same pattern: high-quality studies showed no significant effect in any category. The authors' conclusion is blunt — "there is currently no clinical evidence to support the use of collagen supplements to prevent or treat skin aging."
That is the most important single citation on this page for anyone about to spend money. It does not prove collagen powder does nothing. It shows the positive signal in the literature tracks industry funding and low study quality, which is exactly the pattern you would expect if the effect were small or absent. Anyone selling you collagen for your face should be able to discuss this paper. Most cannot, because they have not read it.
Bone — a genuinely more interesting story
The bone data is smaller but harder to dismiss, because the endpoint is a DXA scan rather than a photograph.
König and colleagues randomised 131 postmenopausal women with reduced bone density (mean age 64) to 5 g of specific collagen peptides or placebo for 12 months; 102 completed. Spine T-score rose 0.1 in the peptide group versus a 0.03 fall on placebo (p=0.030); femoral neck T-score rose 0.09 versus a 0.01 fall (p=0.003). Bone turnover markers moved in the expected direction. The study was part-funded by GELITA, the ingredient manufacturer, though the authors state the analysis was performed solely by the investigators and declare no conflict of interest — a declaration worth reading alongside the fact that one author heads a collagen research institute.
A separate randomised study of 51 postmenopausal women with osteopenia in Greece gave calcium and vitamin D with or without 5 g of collagen peptides for 12 months and found significant gains in trabecular bone mineral content and cross-sectional area at the tibia in the collagen group. A four-year follow-up of a subset of the original König cohort reported continued improvement.
This is thin — a few hundred women in total, across a handful of trials, several with ingredient-industry involvement, and no fracture outcomes at all. It is still more than every injectable peptide on this site has combined. If you are thinking about bone specifically, the muscle and bone guide covers what else is in the running, including the things with much larger evidence bases.
If you're going to buy, buy from someone who tests
ZestyRat publishes batch COAs and third-party purity results. Given that independent testing has found problems in roughly 30% of peptide vials on the market, this is the part that matters most.
Hair loss in midlife: what is studied, and what is claimed
Female pattern hair loss is where the gap between marketing and evidence gets widest, partly because the distress is real and urgent and partly because the genuinely effective options are unglamorous.
What has actually been tested in women
A 2024 network meta-analysis pooled 13 trials of monotherapy in adult women with pattern hair loss, using change in total hair density as the outcome. Topical minoxidil 5% solution twice daily ranked near the top; 5 mg/day finasteride ranked highest but is used off-label in women and carries clear reproductive contraindications. Low-dose oral minoxidil has a growing descriptive literature in women, including a 148-woman single-centre series, though it is off-label and requires blood-pressure awareness. Low-level laser therapy has randomised data of variable quality. Spironolactone is widely used with weaker comparative evidence.
Before any of that: iron studies and thyroid function. Both iron deficiency and thyroid disease are common in perimenopausal women, both cause diffuse shedding, and both are fixable. Starting a peptide before checking a ferritin and a TSH is the most common expensive mistake in this space.
What peptide marketing claims
No human data There is no trial of GHK-Cu alone for hair growth in women. The nearest thing is a 2016 study in Annals of Dermatology that treated 45 patients with male pattern hair loss using a complex of 5-aminolevulinic acid and GHK peptide for six months. Hair count rose significantly in both active groups, but hair length and thickness did not differ, and because GHK was combined with 5-ALA you cannot attribute the result to the peptide. All male. Six months. Forty-five people. That is the entire clinical foundation for copper peptide hair products.
The other frequently cited paper is a 2018 open-label, single-arm pilot of intradermal injections in 1,000 patients — but the formulation contained VEGF, basic FGF, IGF, keratinocyte growth factor, thymosin beta-4 and copper tripeptide-1 together, with no control group. It tells you nothing about copper peptide specifically.
So: copper peptide scalp serums are a low-risk thing to add on top of something that works. They are not a substitute for it, and nobody has tested them in a woman with female pattern hair loss.
What a sensible approach looks like
We do not write protocols and we do not tell anyone what to take. But the ordering below follows the evidence rather than the marketing, and it is what the research on this page supports.
Ordered by how much is actually known
1. Sun protection and a retinoid. Boring, cheap, and the two interventions for facial skin ageing with the largest and most independent human evidence base. Nothing on this page beats them.
2. If you are already considering MHT for other symptoms, know that the skin data exists and is more direct than anything in the peptide category. Discuss it with a clinician who knows your history, not a supplement retailer.
3. For hair: check ferritin and thyroid first, then discuss minoxidil. Peptide serums come after that, not instead.
4. Topical GHK-Cu is a reasonable low-cost addition with real uncertainty about how much it does. Buy it as a cosmetic, expect a cosmetic result, and do not pay clinic prices for it.
5. Oral collagen peptides are cheap, safe and possibly useful for bone density in postmenopausal women; the skin case is weaker than the marketing and weakest in the unfunded trials.
6. Injectable GHK-Cu is the one we would leave alone until somebody publishes a human trial.
Who should be especially careful
Anyone with Wilson's disease or another disorder of copper handling should not take systemic copper in any form. Anyone still able to conceive — and perimenopausal women can — should note that none of these compounds has pregnancy safety data, and finasteride in particular is teratogenic. If you are on hormone therapy, taking other peptides, or being treated for a hormone-sensitive cancer, the interaction questions are real and are covered in our guides on peptides and HRT and weight in perimenopause. Talk to a clinician who knows your history.
Questions people actually ask
Is injectable GHK-Cu better than the serum because it's more bioavailable?
Higher bioavailability only helps if you know what dose to deliver and what it does at that dose. For injected GHK-Cu, neither is known — there are no published human trials for any indication. Meanwhile injection introduces systemic copper exposure that a serum does not. So the greater bioavailability of the injectable route is a reason for more caution, not less.
Does copper peptide really "regulate 4,000 genes"?
The claim traces to gene-expression array work published by Loren Pickart, who owns a copper-peptide skincare company. The array observation is real; the interpretation of it as genomic rejuvenation is the author's framing rather than a demonstrated outcome. Many stimuli shift the expression of thousands of genes in cultured cells. No human trial has tested whether any of it changes how skin looks or behaves.
Will collagen powder help my skin?
Possibly a little, possibly not at all. Several randomised trials in women aged 35–65 found improvements in elasticity and eye wrinkle volume. But a 2025 meta-analysis of 23 trials and 1,474 people found the benefit vanished in studies not funded by industry and in high-quality studies. It is cheap and safe, so trying it is low-stakes. Expect little and you will not be disappointed.
What about collagen for bone density?
This is the better-evidenced use. A 12-month randomised trial in 131 postmenopausal women found small but statistically significant gains in spine and femoral neck T-scores on 5 g/day versus losses on placebo, and a separate 51-woman trial in women with osteopenia found gains in tibial trabecular bone content. Both are small, neither measured fractures, and the larger one was part-funded by the ingredient maker. It is a reasonable low-risk addition to the things that actually build bone — resistance training, adequate protein, vitamin D and calcium.
Has GHK-Cu ever been studied in perimenopausal women?
No. Searching PubMed for GHK-Cu together with menopause, perimenopause or postmenopausal status returns zero results. Of roughly 220 indexed GHK-Cu papers, only four carry both human and female tags. Nobody has tested this in the population it is chiefly sold to.
Can I use copper peptide serum and a retinoid or vitamin C together?
No trial has tested the combination, so any answer is formulation chemistry rather than clinical evidence. The common practical advice is to separate them — copper peptide in one routine, retinoid or L-ascorbic acid in the other — mainly to avoid irritation and because low pH can affect peptide stability. That is a reasonable precaution, not a proven requirement.
Does any peptide regrow hair in women?
Nothing in the peptide category has been shown to. The only GHK hair trial used a combination product in 45 men, and the widely cited 1,000-patient injection study used a six-ingredient formulation with no control group. Topical minoxidil has the strongest evidence in women. If shedding is new or rapid, get ferritin and thyroid function checked before spending anything.
If you came here from a symptom rather than a compound, the rest of the guides pick up where this one stops: energy and brain fog, sleep, libido and mood, weight, muscle and bone, and peptides alongside HRT.
And if you want the pretty one: Amino Club.
ZestyRat is the supplier that looks like it was built for somebody else and works for everyone. Amino Club is the one that looks like it was built for you — soft branding, clean packaging, ISO 17025 third-party certificates, US shipping. It is our genuine second choice and the code SHAUN22 works there. Second, not first, for one reason: ZestyRat has never once given us a story to tell.
Sources
- Brincat MP, Baron YM, Galea R. Estrogens and the skin. Climacteric 2005;8(2):110-23. PMID 16096167.
- Affinito P, Palomba S, Sorrentino C, et al. Effects of postmenopausal hypoestrogenism on skin collagen. Maturitas 1999;33(3):239-47. PMID 10656502.
- Pivazyan L, Avetisyan J, Loshkareva M, Abdurakhmanova A. Skin rejuvenation in women using menopausal hormone therapy: a systematic review and meta-analysis. J Menopausal Med 2023;29(3):97-111. PMID 38230593.
- Mayfield CK, Bolia IK, Feingold CL, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med 2026;54(1):223-229. PMID 41476424.
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008;19(8):969-88. PMID 18644225.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015;2015:648108. PMID 26236730.
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018;19(7):1987. PMID 29986520.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. Biomed Res Int 2014;2014:151479. PMID 25302294.
- Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res 2011;60(1):79-86. PMID 20721598.
- National Institutes of Health, Office of Dietary Supplements. Copper: fact sheet for health professionals. Accessed September 2026.
- Proksch E, Segger D, Degwert J, et al. Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology: a double-blind, placebo-controlled study. Skin Pharmacol Physiol 2014;27(1):47-55. PMID 23949208.
- Proksch E, Schunck M, Zague V, et al. Oral intake of specific bioactive collagen peptides reduces skin wrinkles and increases dermal matrix synthesis. Skin Pharmacol Physiol 2014;27(3):113-9. PMID 24401291.
- Myung SK, Park Y. Effects of collagen supplements on skin aging: a systematic review and meta-analysis of randomized controlled trials. Am J Med 2025;138(9):1264-1277. PMID 40324552.
- König D, Oesser S, Scharla S, et al. Specific collagen peptides improve bone mineral density and bone markers in postmenopausal women: a randomized controlled study. Nutrients 2018;10(1):97. PMID 29337906.
- Zdzieblik D, Oesser S, König D. Specific bioactive collagen peptides in osteopenia and osteoporosis: long-term observation in postmenopausal women. J Bone Metab 2021;28(3):207-213. PMID 34520654.
- Lampropoulou-Adamidou K, Karlafti E, Argyrou C, et al. Effect of calcium and vitamin D supplementation with and without collagen peptides on volumetric and areal bone mineral density, bone geometry and bone turnover in postmenopausal women with osteopenia. J Clin Densitom 2022;25(3):357-372. PMID 34980546.
- Gupta AK, Wang T, Bamimore MA, et al. The relative effect of monotherapy with 5-alpha reductase inhibitors and minoxidil for female pattern hair loss: a network meta-analysis study. J Cosmet Dermatol 2024;23(1):154-160. PMID 37386777.
- Rodrigues-Barata R, Moreno-Arrones OM, Saceda-Corralo D, et al. Low-dose oral minoxidil for female pattern hair loss: a unicenter descriptive study of 148 women. Skin Appendage Disord 2020;6(3):175-176. PMID 32656239.
- Lee WJ, Sim HB, Jang YH, et al. Efficacy of a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide on hair growth. Ann Dermatol 2016;28(4):438-43. PMID 27489425.
- Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth: safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther 2018;20(6):369-379. PMID 29482481.